Get the Stockscreener App
5.71
2.39%
-0.14
After Hours:
5.75
0.04
+0.70%
Satellos Bioscience Inc stock is traded at $5.71, with a volume of 26,220.
It is down -2.39% in the last 24 hours and down -20.14% over the past month.
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.
See More
Previous Close:
$5.85
Open:
$5.97
24h Volume:
26,220
Relative Volume:
0.45
Market Cap:
$118.95M
Revenue:
-
Net Income/Loss:
$-28.50M
P/E Ratio:
-3.1498
EPS:
-1.8128
Net Cash Flow:
$-25.87M
1W Performance:
-3.22%
1M Performance:
-20.14%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$5.68
$5.97
1-Week Range:
$5.61
$5.97
52-Week Range:
$5.50
$13.39
Satellos Bioscience Inc Stock (MSLE) Company Profile
Name
Satellos Bioscience Inc
Sector
Industry
Phone
-
Address
-
Compare MSLE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MSLE
Satellos Bioscience Inc
|
5.71 | 121.86M | 0 | -28.50M | -25.87M | -1.8128 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 116.49B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.73B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 55.49B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.75B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 33.54B | 742.00K | -1.37B | -1.07B | -7.0731 |
Satellos Bioscience Inc Stock (MSLE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-06-26 | Initiated | Leerink Partners | Outperform |
| Mar-11-26 | Initiated | Cantor Fitzgerald | Overweight |
Satellos Bioscience Inc Stock (MSLE) Latest News
Satellos Bioscience Ord Shs (MSLE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Satellos Bioscience Shareholders Back Board Slate and Auditor at June 17 Annual Meeting - TipRanks
Satellos Bioscience Shareholders Back Board Slate and Auditor at June 17 AGM - TipRanks
Satellos Bioscience (NASDAQ: MSLE) details 2026 director election vote results - Stock Titan
Satellos Bioscience Announces Results of Annual Meeting of Shareholders - GlobeNewswire
Why Satellos Bioscience Inc. stock is rising today - Wealth Awesome
MSLE Q1 2026 Earnings: Narrower Loss Beats Expectations as Pipeline AdvancesProfit Inflection Point - newsline.com
MSLE Q1 2026 Earnings: Smaller-than-Expected Loss as Positive EPS Surprise Drives Focus on Drug Development ProgressEarnings Growth Forecast - newsline.com
Satellos Bioscience (MSLE) Slips 2.54% as Stock Tests Key Support Near $5.46Dividend Arbitrage - newsline.com
Why Satellos Bioscience Inc. stock is sliding today - Wealth Awesome
Satellos Bioscience Q1 2026 Earnings: Narrower-Than-Expected Loss as DMD Program AdvancesProfit Cycle Analysis - newsline.com
Why Satellos Bioscience Inc. stock is gaining today - Wealth Awesome
Satellos Bioscience Inc Company Profile & Introduction - Moomoo
MSLE SEC FilingsSatellos Bioscience Inc 10-K, 10-Q, 8-K Forms - Stock Titan
MSLE Q1 2026 Earnings: Narrower-than-Expected Loss Amid Pre-Clinical Cash BurnGuidance vs Actual - newsline.com
Satellos Bioscience Inc Financial Disclosures & Filings - TradingView
Insider Traders Lose US$134k As Satellos Bioscience Drops - simplywall.st
Satellos Bioscience (MSCL) Investor Relations, Earnings Summary & Outlook - Quartr
Leerink initiates Satellos Bioscience stock with Outperform rating - Investing.com
MSLE Q1 2026 Earnings: Narrower-Than-Expected Net Loss Highlights Cost Discipline Amid Pre-Revenue StatusForward EPS Estimate - newsline.com
Satellos Bioscience (MSLE) Surges 9%: Volume Spike Tests Key Resistance ZoneMESA MA - The Legal Advocate
Satellos to Participate in Upcoming Investor Conferences - Investing News Network
Satellos Bioscience to Highlight Neuromuscular Pipeline at June Investor Conferences - TipRanks
Satellos Bioscience (NASDAQ: MSLE) to present SAT-3247 program at June investor conferences - Stock Titan
Satellos Bioscience (MSLE) Surges 7% as Biotech Stock Breaks Above Key SupportBearish Pattern Stocks - newsline.com
Satellos Bioscience (MSLE) Slides 5.5% as Biotech Sector Headwinds Weigh on SentimentHidden Order - Newser
Satellos Bioscience Q1 2026 Earnings: Narrower Loss Reported, Stock Slips on Lack of Revenue Progress - Newser
MSLE Q1 2026 Earnings: EPS Beats Expectations Despite No Revenue; Shares DeclineEarnings Cycle Report - newsline.com
Satellos Bioscience Inc. (MSLE) Q1 2026 Earnings: Narrower-Than-Expected Loss Marks Progress Amid Pre-Revenue StageCEO Earnings Statement - Newser
CCORF Initiates Satellos Bioscience(MSLE.US) With Buy Rating, Announces Target Price $13.81 - Moomoo
Satellos Bioscience Price Target Maintained With a $11.00/Share by HC Wainwright & Co. - Moomoo
Satellos Bioscience Sets June 17, 2026 Virtual Annual Shareholder Meeting - TipRanks
Virtual AGM, board elections and pay disclosure at Satellos Bioscience (NASDAQ: MSLE) - Stock Titan
Satellos Bioscience (MSLE) Stock Analysis: Flat at $7.15, What's Next 2026-05-19Mid Cap Momentum - newsline.com
MSLE Reiterated by HC Wainwright & Co. -- Price Target Maintained at $11 - GuruFocus
Satellos Bioscience (MSLE) Q1 2026 Earnings: EPS $-0.53 Beats EstimatesHigh Attention Stocks - newser.com
Satellos Bioscience (TSX:MSCL) Extends Cash Runway Confidence - Kalkine Media
H.C. Wainwright Maintains Satellos Bioscience(MSLE.US) With Buy Rating, Maintains Target Price $11 - Moomoo
We're Not Very Worried About Satellos Bioscience's (TSE:MSCL) Cash Burn Rate - Yahoo Finance
Stocks In Play - Baystreet.ca
Satellos Bioscience (MSLE) insiders report 1.14M shares, 7.35% stake - Stock Titan
Positive Developments for Satellos (MSLE) in Q1 2026 - GuruFocus
Satellos Bioscience Inc. - Baystreet.ca
Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress - Investing News Network
Satellos Bioscience : First Quarter 2026 Management’s Discussion Analysis - marketscreener.com
Satellos Bioscience Posts Wider Q1 2026 Loss but Strengthens Balance Sheet - TipRanks
Satellos Bioscience: Q1 Earnings Snapshot - marketscreener.com
Satellos Bioscience (NASDAQ: MSLE) raises $57M and advances Duchenne trials - Stock Titan
MSLE Price Today: Satellos Bioscience Inc. Stock Price, Quote & Chart | MEXC - MEXC
Qiming reports 1.725M Satellos shares; MSLE ownership disclosure - Stock Titan
Number of shareholders of Satellos Bioscience Inc. – BOATS:MSLE - TradingView
Satellos Bioscience Inc Stock (MSLE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):